169318-07-4

Upstream product

• 15403-22-2 4-(3-hydroxy-propyl)-benzoic acid methyl ester 
• 105-56-6 ethyl 2-cyanoacetate 
• 1972-28-7 diethylazodicarboxylate 
• 497-19-8 sodium carbonate 
• 141018-99-7 methyl 4-<3-(methanesulfonyloxy)propyl>benzoate 
• 61266-36-2 methyl 4-(3-hydroxypropynyl)benzoate 
• 619-44-3 methyl 4-iodobenzoate 

Downstream Products

• 169318-05-2 4-[3-(2,4-Diamino-6-oxo-1,6-dihydro-pyrimidin-5-yl)-propyl]-benzoic acid methyl ester 
• 169318-08-5 N-{[4-(2,6-diamino-4-chloro-5-pyrimidinyl)propyl]benzoyl}-L-glutamic acid di-t-butyl ester 
• 169318-09-6 N-{[4-(2,4-diamino-5-pyrimidinyl)propyl]benzoyl}-L-glutamic acid di-t-butyl ester 
• 169318-02-9 4-[3-(2,4-Diamino-6-chloro-pyrimidin-5-yl)-propyl]-benzoic acid 
• 169318-01-8 4-[3-(2,4-Diamino-6-oxo-1,6-dihydro-pyrimidin-5-yl)-propyl]-benzoic acid 

Relevant academic research and scientific papers

Synthesis and biological evaluation of a new series of dihydrofolate reductase inhibitors based on the 4-(2,6-diamino-5-pyrimidinyl)alkyl-L-glutamic acid structure

A novel series of dihydrofolate reductase inhibitors was uncovered during an expansion of the SAR of 5,10-dideazatetrahydrofolic acid, and their biological activity was evaluated. These new analogs do not possess an oxygen at the 4 position and contain a

PYRIMIDINYL-GLUTAMIC ACID DERIVATIVES

The present invention provides novel pyrimidinyl-glutamic acid derivatives and intermediates thereto. Further provided are methods for inhibiting dihydrofolate reductase in mammals and for treating susceptible neoplasms in mammals, particularly humans.